Against the backdrop of the gradual recovery of the global economy and accelerated technological iteration, the pharmaceutical industry is unleashing new vitality, especially in the field of innovative drugs, which is attracting more and more attention and resources.

From the perspective of market performance, innovative pharmaceutical company ETFs have shown impressive performance recently. As of the midday closing on March 21, 2025, despite fluctuations in intraday trading volume, the cumulative increase in the past week has reached 3.94%, ranking among the top in comparable funds. It is worth noting that the ETF received a net inflow of funds against the market yesterday, becoming a gathering place for funds among similar products.

Behind this capital flow is a positive signal for the global pharmaceutical investment and financing market.

In 2024, biopharmaceutical projects will dominate in terms of investment and financing transaction scale and activity, followed closely by equipment and consumables projects. Among them, AI+pharmaceuticals, weight loss drugs, and autoimmune drugs have shown particularly outstanding performance, with frequent financing events exceeding billions of dollars. Innovative projects such as gene therapy, immunotherapy, and targeted therapy are also highly favored by capital.

The CSI Innovation Drug Industry Index, closely tracked by the Innovation Drug ETF, selects the most representative 50 sample stocks from numerous innovation drug research and development companies, accurately reflecting the overall performance of the innovation drug industry. This makes the ETF a high-quality tool for investors to layout in the field of innovative drugs.

With the rise of a new wave of technology driven by AI technology, Morgan Asset Management and other institutions have integrated their technology investment product lines to help investors layout high-quality technology enterprises from a global perspective and seize opportunities of the times. In the pharmaceutical industry, products such as Morgan Stanley CSI Innovative Pharmaceutical Industry ETF provide investors with a convenient channel to layout Chinese innovative pharmaceutical companies.

Currently, the wave of pharmaceutical innovation is driving the industry forward, and the performance of innovative pharmaceutical companies in the capital market is receiving increasing attention. Whether it is the warming of the global pharmaceutical investment and financing market or the inflow of funds from innovative pharmaceutical company ETFs, it indicates that the pharmaceutical industry is standing at a new starting point for development, and is expected to continue to bring substantial returns to investors in the future. At the same time, it will inject stronger momentum into global pharmaceutical research and innovation.